<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477100</url>
  </required_header>
  <id_info>
    <org_study_id>2006-1072</org_study_id>
    <secondary_id>NCI-2018-01784</secondary_id>
    <secondary_id>2006-1072</secondary_id>
    <nct_id>NCT00477100</nct_id>
  </id_info>
  <brief_title>Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer</brief_title>
  <official_title>Inflammatory Breast Cancer (IBC) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Appropriation for Rare and Aggressive diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies the biospecimen and medical data collection in creating a research tissue&#xD;
      registry in patients with inflammatory or invasive breast cancer. Collecting medical data and&#xD;
      storing samples of blood, tissue, and stool from patients with inflammatory breast cancer to&#xD;
      study in the laboratory may help doctors find better ways to treat and study inflammatory&#xD;
      breast cancer in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To prospectively collect tissue (including primary inflammatory breast cancer [IBC],&#xD;
      ipsilateral nodal metastasis and/or distant metastasis [if applicable] obtained prior to&#xD;
      primary systemic therapy and mastectomy/axillary dissection), serum, plasma, whole blood,&#xD;
      clinical, and imaging data from patients with recently diagnosed inflammatory breast cancer&#xD;
      (IBC), or highly suspicious for IBC, who have not received systemic therapy.&#xD;
&#xD;
      II. To collect paraffin tissue blocks or unstained slides (including primary, ipsilateral&#xD;
      nodal metastasis and/or distant metastasis [if applicable] obtained prior to primary systemic&#xD;
      therapy), mastectomy/axillary dissection tissue, serum, plasma, whole blood, clinical, and&#xD;
      imaging data (if available) from patients with previously diagnosed inflammatory breast&#xD;
      cancer (IBC), who have been treated or partially treated, but have not had mastectomy and are&#xD;
      seeking further treatment in the IBC clinic at M. D. Anderson or participating cancer network&#xD;
      sites.&#xD;
&#xD;
      III. To collect oral swab, skin and stool bacterial culture swab for microbiome analysis to&#xD;
      compare patients with specific breast cancer subtype to report changes in flora during the&#xD;
      course of treatment and correlated to toxicity.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients complete questionnaires and participate in interview over 30 minutes. Patients also&#xD;
      undergo collection of medical data and blood, tissue, and stool samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2007</start_date>
  <completion_date type="Anticipated">April 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Data, serum, tissue, peripheral blood mononuclear cells, and plasma sample collection</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>No statistical considerations are provided. For each clinical question that will use the data collected in this registry, a separate protocol will be submitted to the Institutional Review Board (IRB) that will include a sample size justification and an analysis plan.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Inflammatory Breast Carcinoma</condition>
  <condition>Invasive Breast Carcinoma</condition>
  <condition>Second Primary Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Observational (biospecimen and medical data collection)</arm_group_label>
    <description>Patients complete questionnaires and participate in interview over 30 minutes. Patients also undergo collection of medical data and blood, tissue, and stool samples.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood, tissue, and stool</description>
    <arm_group_label>Observational (biospecimen and medical data collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>Participate in interview</description>
    <arm_group_label>Observational (biospecimen and medical data collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Chart Review</intervention_name>
    <description>Undergo collection of medical data</description>
    <arm_group_label>Observational (biospecimen and medical data collection)</arm_group_label>
    <other_name>Chart Review</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Observational (biospecimen and medical data collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, tissue, stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with inflammatory or invasive breast cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with clinical diagnosis of primary inflammatory breast cancer (IBC), second&#xD;
             primary IBC, or highly suspicious for IBC (MD Anderson patients only).&#xD;
&#xD;
          -  Histological diagnosis of invasive breast cancer, or highly suspicious for IBC (MD&#xD;
             Anderson patients only) but pending breast cancer diagnosis.&#xD;
&#xD;
          -  Be either newly diagnosed, or highly suspicious for IBC (MD Anderson patients only)&#xD;
             [Cohort I] or have paraffin blocks or up to 20 unstained slides of each representative&#xD;
             block(s) from the time of initial diagnosis of IBC(i.e. core biopsy and punch biopsy)&#xD;
             and/or from mastectomy (Cohort II-MD Anderson patients only)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoto T Ueno</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Willey</last_name>
    <phone>713-792-3965</phone>
    <email>jwilley@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoto T. Ueno</last_name>
      <phone>713-792-2817</phone>
    </contact>
    <investigator>
      <last_name>Naoto T. Ueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in Katy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoto T. Ueno</last_name>
      <phone>713-792-8754</phone>
      <email>nueno@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naoto T. Ueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson League City</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoto T. Ueno</last_name>
      <phone>713-792-8754</phone>
      <email>nueno@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naoto T. Ueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoto T. Ueno</last_name>
      <phone>713-792-8754</phone>
      <email>nueno@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naoto T. Ueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoto T. Ueno</last_name>
      <phone>713-792-8754</phone>
      <email>nueno@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naoto T. Ueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Spain</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

